Drugs / CB-10-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00925314 | Jun 2007 → Jul 2011 | cutaneous melanoma | Cosmo Bioscience | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CB-10-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00925314 ↗ |
| Known as | Transgenic Lymphocyte Immunization | “The Investigational Product, Transgenic Lymphocyte Immunization (TLI), is aimed at helping the immune system target this enzyme found in most cancerous cells.” NCT00925314 ↗ |